
Sudeep Pharma IPO
- Issue price
- ₹593
- Listing price
- ₹730
- +23.10%
- Current price
- ₹1,198.7
- +102.14%
- Subscribed
- 93.72x
- Issue size
- ₹895 Cr
- Listed on
- 28 Nov 2025
IPO timeline
- Opens21 NovFri
- Closes25 NovTue
- Allotment26 NovWed
- Refunds27 NovThu
- Demat credit27 AugWed
- Listing28 NovFri
Issue details
- Price band
- ₹563 – ₹593 per share
- Issue size
- ₹895 Cr
- Fresh issue
- Not available
- Offer for sale
- Not available
- Issue type
- Fresh capital cum OFS
- Face value
- ₹1 per share
- Lot size
- 25 shares
- Minimum investment
- ₹14,825
- Listing on
- BSE & NSE
- Exchange code
- SUDEEPPHRM.BO · 7455
This issue combines a fresh issue and an offer for sale. The amounts for each part are not available in our data; see the offer document for the split.
Lot size and investment
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 25 | ₹14,825 |
| Retail (Max) | 13 | 325 | ₹1,92,725 |
| S-HNI (Min) | 14 | 350 | ₹2,07,550 |
| B-HNI (Min) | 68 | 1,700 | ₹10,08,100 |
Reservation
- QIB
- 75,46,373 shares (50.00% of the Offer)
- NII
- 22,63,913 shares (15.00% of the Offer)
- Retail
- 52,82,463 shares (35.00% of the Offer)
Allotment status
The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).
Check allotment on MUFG Intime India- 1Open the registrar's allotment page and select this IPO from the list.
- 2Enter your PAN, application number or DP / Client ID.
- 3Submit to see the number of shares allotted, if any.
- Basis of allotment
- 26 Nov 2025
- Refunds initiated
- 27 Nov 2025
- Shares credited to demat
- 27 Aug 2025
- Listing
- 28 Nov 2025
Grey market premium (GMP)
- Current GMP
- ₹93
- +16.00%
- Estimated listing price
- ₹686
- Issue price ₹593
- Kostak rate
- ₹0
GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.
Subscription status
- QIB213.08x
- NII (HNI)116.72x
- Retail15.65x
| Category | Shares offered | Shares bid for | Subscribed |
|---|---|---|---|
| Qualified Institutional Buyers (QIB) | 30,18,550 | 64,31,88,450 | 213.08x |
| Non-Institutional Investors (NII) | 22,63,913 | 26,42,40,450 | 116.72x |
| bNII — bids above ₹10 Lakh | 15,09,276 | 20,36,19,700 | 134.91x |
| sNII — bids ₹2 Lakh to ₹10 Lakh | 7,54,637 | 6,06,20,750 | 80.33x |
| Retail Individual Investors (RII) | 52,82,463 | 8,26,71,250 | 15.65x |
| Total | 1,05,64,926 | 99,01,00,150 | 93.72x |
Financials
- P/E Ratio
- 53.55
- EPS (₹)
- 11.07
- RoCE
- 35
- RoNW
- 27.88
- PAT Margin
- 27.63
Separate pre- and post-issue P/E are not available for this IPO; the P/E shown is as disclosed for the issue.
| Period ended | 31 Mar 24 | 31 Mar 23 | 31 Mar 22 |
|---|---|---|---|
| Revenue | 565.55 | 959.21 | 475.51 |
| OPM % | 7.65 | ||
| EBITDA | 84.11 | 107.97 | 57.82 |
| Net Profit | -16.98 | -102.35 | -71.70 |
| Debt | 533.51 | 437.06 | 384.79 |
| Assets | 2,134.35 | 1,859.84 | 1,863.50 |
Peer comparison
| Company | Issue size | P/E | RoNW | PAT margin | Subscribed | Listing gain |
|---|---|---|---|---|---|---|
| Sudeep Pharma This IPO | ₹895 Cr | 53.55 | 27.88% | 27.63% | 93.72x | +23.10% |
| Nephrocare Health Services Mainboard · listed 17 Dec 2025 | ₹871.05 Cr | 162.19 | 13.19% | 8.88% | 13.96x | +6.52% |
| Park Medi World Mainboard · listed 17 Dec 2025 | ₹920 Cr | 63.52 | 13.19% | 8.88% | 8.1x | -1.98% |
| Ellenbarrie Industrial Gases Mainboard · listed 1 Jul 2025 | ₹852.53 Cr | 67.69 | 24.97% | 23.90% | 22.47x | +21.50% |
| Molbio Diagnostics Mainboard · listed 17 Aug 2026 | ₹939.7 Cr | 56.67 | 14.55% | 11.28% | 70.26x | +21.44% |
| Suraksha Diagnostic Mainboard · listed 6 Dec 2024 | ₹846.25 Cr | 74.89 | 14.09% | 10.57% | 1.27x | -0.68% |
| Fusion CX Mainboard · listed 22 Oct 2026 | ₹702 Cr | 18.73 | 9.12% | 11.36% | 4.45x | +5.54% |
Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.
IPO objectives
How Sudeep Pharma plans to use the money raised, as stated in the offer document.
- Capital expenditure towards procurement of machinery for the production line located at Nandesari Facility I ₹75.81 Cr
- General corporate purposes₹12.67 Cr
About Sudeep Pharma
Sudeep Pharma Limited is an India-based pharmaceutical company known for its specialization in mineral-based excipients and active ingredients used across pharma, nutraceutical, and food industries. Established with a focus on quality and innovation, the company has built a strong presence over the years by catering to both domestic and international markets. Promoted by experienced industry professionals, Sudeep Pharma has developed deep technical expertise and a reputation for consistent product standards, regulatory compliance, and customer-centric operations. The company primarily manufactures calcium-based and mineral ingredients such as calcium carbonate, calcium citrate, and other specialty compounds widely used in tablets, dietary supplements, and fortified food products. Its business model is largely B2B, supplying to pharmaceutical companies, nutraceutical brands, and global distributors. By focusing on quality certifications, scalable manufacturing, and long-term client relationships, the company aims to sustain growth and expand its footprint in regulated and semi-regulated markets worldwide.
Promoters and shareholding
Avani Sujit Bhayani, Bhayani Family Trust, Riva Resources Pvt.Ltd, Shanil Sujit Bhayani, Sujeet Jaysukh Bhayani (HUF), Sujit Jaysukh Bhayani
- Promoter holding, pre-issue
- 89.37%
- Promoter holding, post-issue
- 76.15%
Registrar, lead managers and documents
Lead managers
Company contact
129/1/A, GIDC Estate, Nandesari, Vadodara, Gujarat, 391340
+91 265 284 0656
cs.sudeep@sudeepgroup.comSudeep Pharma IPO: common questions
1.When does the Sudeep Pharma IPO open and close?
The Sudeep Pharma IPO opens on 21 Nov 2025 and closes on 25 Nov 2025.
2.What is the price band of the Sudeep Pharma IPO?
The price band is ₹563 – ₹593 per share, with a lot size of 25 shares and a minimum investment of ₹14,825.
3.What is the size of the Sudeep Pharma IPO?
The issue size is ₹895 Cr (Fresh capital cum OFS).
4.What is the GMP of the Sudeep Pharma IPO?
The last reported grey market premium is ₹93 per share as of 19 Nov 2025, 12:00 PM IST. GMP is unofficial and changes frequently.
5.When is the Sudeep Pharma IPO allotment?
The basis of allotment is expected on 26 Nov 2025. Allotment status can be checked with the registrar, MUFG Intime India Private Limited.
6.When will the Sudeep Pharma IPO list?
The shares listed on 28 Nov 2025 on BSE & NSE.
7.Who is the lead manager of the Sudeep Pharma IPO?
The book running lead managers are ICICI Securities, IIFL Capital Services Limited, and the registrar is MUFG Intime India Private Limited.
8.What will the money raised in the Sudeep Pharma IPO be used for?
As stated in the offer document, the proceeds are for: Capital expenditure towards procurement of machinery for the production line located at Nandesari Facility I ; General corporate purposes.
9.How can my company launch an IPO like Sudeep Pharma?
Start with an IPO readiness assessment: eligibility for the Main Board, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.
For business owners
Your company could be the next listing
Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.
- Eligibility check against NSE Emerge, BSE SME and Main Board norms
- Indicative valuation and issue size for your business
- A clear timeline from readiness to listing day
Check if your business can list
Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.
Prefer to talk? Call +91 92130 20393